# VenoStent **Source:** https://geo.sig.ai/brands/venostent **Vertical:** Healthcare **Subcategory:** General **Tier:** Challenger **Website:** venostent.com **Last Updated:** 2026-04-14 ## Summary Houston TX YC W20 clinical-stage AV fistula wrap for dialysis patients with 200-patient RCT underway; $22.8M total ($20M Good Growth/Norwest Series A Jun 2024 + $3.6M NIH grant) targeting vascular access failure competing for dialysis market. ## Company Overview VenoStent is a Houston, Texas-based clinical-stage medical device company — backed by Y Combinator (W20) with $22.8 million in total funding including a $20 million Series A in June 2024 led by Good Growth Capital and IAG Capital Partners with $4 million from Norwest Venture Partners, plus a $3.6 million NIH SBIR Phase II Grant — developing SelfWrap, a bioabsorbable perivascular wrap designed to improve arteriovenous (AV) fistula patency rates for chronic kidney disease patients requiring hemodialysis access. Having initiated clinical sites and enrolled first patients in a 200-patient randomized controlled trial (RCT) across multiple US centers in 2024, VenoStent targets the 600,000+ American dialysis patients who depend on reliable vascular access as their lifeline. VenoStent's SelfWrap perivascular device addresses the AV fistula failure rate that is the leading cause of hospitalization and morbidity in dialysis patients: an AV fistula (a surgical connection between an artery and vein in the forearm that creates a high-flow vascular access point for dialysis needle cannulation) fails to mature into a usable access in 20-60% of cases due to neointimal hyperplasia — the body's smooth muscle cell proliferation response to surgical trauma that narrows the vein and prevents adequate blood flow for dialysis. SelfWrap's bioabsorbable outer wrap (applied around the vein at the time of fistula creation, providing mechanical support and controlled drug delivery to modulate the healing response) is designed to reduce the hyperplasia cascade that causes fistula failure — improving the primary patency rates that determine whether a dialysis patient uses their own fistula or requires a catheter (which carries 3x higher infection risk and 2x higher mortality). In 2025, VenoStent competes in the hemodialysis vascular access, endovascular devices, and chronic kidney disease management market with Merit Medical (NASDAQ: MMSI, vascular access products, $1.2B revenue), BD (NYSE: BDX, hemodialysis catheter market leader, $20B revenue), and Vasc-Alert (AV access monitoring) for dialysis center and vascular surgery adoption of AV fistula maturation improvement devices. Good Growth Capital's Series A leadership and Norwest Venture Partners' participation reflect medtech venture conviction in vascular access innovation. NIH SBIR Phase II grant validation confirms scientific merit. Y Combinator W20 backing (unusual for a medical device company) connects VenoStent with the healthcare technology investor community. The 2025 strategy focuses on completing RCT enrollment across US dialysis and vascular surgery centers, building the clinical outcomes dataset for FDA De Novo or 510(k) submission, and engaging the dialysis network operators (DaVita, Fresenius) as commercial launch channels. ## Frequently Asked Questions ### What is VenoStent? VenoStent is a clinical-stage therapeutic medical device company founded in 2019 and based in Houston, Texas. The company develops SelfWrap, a bioabsorbable perivascular wrap designed to improve arteriovenous fistula outcomes for chronic kidney disease patients requiring hemodialysis. ### What products does VenoStent offer? VenoStent's primary product is SelfWrap, a bioabsorbable perivascular wrap that enhances arteriovenous fistulas and improves dialysis access for hemodialysis patients. The device is designed specifically for chronic kidney disease (CKD) patients requiring dialysis treatment. ### Who is VenoStent's technology designed for? VenoStent's SelfWrap device is designed for chronic kidney disease (CKD) patients who require hemodialysis treatment. The technology targets patients needing arteriovenous fistula access for their dialysis procedures. ### When was VenoStent founded? VenoStent was founded in 2019 in Houston, Texas. The company was also backed by Y Combinator as part of their Winter 2020 (W20) batch. ### Where is VenoStent located? VenoStent is based in Houston, Texas. The company is conducting its clinical trials at multiple centers across the United States. ### How much funding has VenoStent raised? VenoStent has raised $22.8 million in total funding, including a $20 million Series A round in June 2024 led by Good Growth Capital and IAG Capital Partners with $4 million from Norwest Venture Partners. The company also received a $3.6 million SBIR Phase II Grant from the NIH. ### What are VenoStent's key achievements? In 2024, VenoStent initiated its first clinical sites and enrolled the first patients in a 200-patient randomized controlled trial (RCT) across multiple US centers. The company also successfully raised $22.8 million in total funding and is backed by Y Combinator (W20). ### What technology does VenoStent use? VenoStent's SelfWrap is a bioabsorbable perivascular wrap that is applied around arteriovenous fistulas. The bioabsorbable design means the device gradually dissolves over time while providing therapeutic support to improve fistula outcomes for dialysis patients. ### What stage of development is VenoStent in? VenoStent is currently in the clinical stage, having initiated a 200-patient randomized controlled trial (RCT) in 2024. The company has enrolled its first patients at multiple clinical sites across the United States. ### What are VenoStent's most recent developments? In 2024, VenoStent raised $20 million in Series A funding led by Good Growth Capital and IAG Capital Partners, and initiated its first clinical trial with patient enrollment beginning at multiple US sites. The company is conducting a 200-patient randomized controlled trial to evaluate the SelfWrap device. ## Tags healthtech, saas, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*